Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Glaxosmithkline Plc (GSK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 104,909,896
  • Shares Outstanding, K 2,459,210
  • Annual Sales, $ 37,798 M
  • Annual Income, $ 1,236 M
  • 36-Month Beta 1.04
  • Price/Sales 2.78
  • Price/Cash Flow 10.70
  • Price/Book 15.18

Price Performance

See More
Period Period Low Period High Performance
1-Month
41.80 +0.38%
on 07/11/17
44.44 -5.58%
on 06/26/17
-2.33 (-5.26%)
since 06/23/17
3-Month
40.45 +3.73%
on 04/27/17
44.53 -5.77%
on 05/31/17
+0.48 (+1.16%)
since 04/25/17
52-Week
37.20 +12.80%
on 12/08/16
45.58 -7.94%
on 08/02/16
-2.08 (-4.72%)
since 07/25/16

Most Recent Stories

More News
Drug Stocks Q2 Earnings Releases on Jul 26: GILD, VRTX, GSK

We have three pharma giants that are set to report second-quarter results on Jul 26. Let's see how things are shaping up for this quarter.

JNJ : 131.88 (-0.85%)
LLY : 82.19 (-3.01%)
VRTX : 161.97 (-2.49%)
NVS : 84.20 (-0.11%)
GILD : 73.74 (-0.87%)
GSK : 41.96 (-0.66%)
BIIB : 282.96 (-0.61%)
ViiV Healthcare Announces Superior Efficacy of Dolutegravir Versus Lopinavir/Ritonavir in Second-line HIV Treatment in Resource-limited Settings

LONDON, July 25, 2017 /PRNewswire/ --

GSK : 41.96 (-0.66%)
PFE : 33.10 (-0.66%)
Corporate News Blog - GlaxoSmithKline and Innoviva Submits EU Filing for Extended Use of Relvar Ellipta in Patients with Controlled Asthma

LONDON, UK / ACCESSWIRE / July 25, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for GlaxoSmithKline PLC (NYSE: GSK), following which we have published...

INVA : 13.11 (+1.00%)
GSK : 41.96 (-0.66%)
Global Liver Disease Treatment Market 2017-2021: Key Vendors are F. Hoffmann-la Roche, Gilead, GlaxoSmithKline & Merck - Research and Markets

The "Global Liver Disease Treatment Market 2017-2021" report has been added to Research and Markets' offering.

MRK : 62.36 (-0.34%)
GSK : 41.96 (-0.66%)
The Zacks Analyst Blog Highlights: Alphabet, GlaxoSmithKline, T-Mobile, Northrop Grumman and CSX

The Zacks Analyst Blog Highlights: Alphabet, GlaxoSmithKline, T-Mobile, Northrop Grumman and CSX

TMUS : 62.36 (-0.27%)
GOOGL : 969.03 (-2.93%)
NOC : 264.05 (-0.46%)
CSX : 51.56 (+1.46%)
GSK : 41.96 (-0.66%)
Top Stock Reports for Alphabet, GlaxoSmithKline & T-Mobile

Top Stock Reports for Alphabet, GlaxoSmithKline & T-Mobile

TMUS : 62.36 (-0.27%)
GOOGL : 969.03 (-2.93%)
NOC : 264.05 (-0.46%)
CSX : 51.56 (+1.46%)
EOG : 94.87 (+1.67%)
GSK : 41.96 (-0.66%)
Lupus Research Alliance Welcomes Self-Injectable Form of Belimumab

The Lupus Research Alliance congratulates GlaxoSmithKline (GSK) on the approval of belimumab (Benlysta®) by the U.S. Food and Drug Administration as a self-injectable (subcutaneous) formulation for people...

GSK : 41.96 (-0.66%)
GSK Submits EU Filing for Extended Use of Relvar Ellipta in Patients with Controlled Asthma on an ICS/LABA Combination

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced a submission to the European Medicines Agency (EMA) for the extended use of once-daily Relvar Ellipta...

INVA : 13.11 (+1.00%)
GSK : 41.96 (-0.66%)
Emergent Inks Agreement to Acquire Anthrax Drug Raxibacumab

Emergent's shares inched up post announcement of its deal inked with GlaxoSmithKline to acquire the latter's anthrax monoclonal antibody raxibacumab.

ENZ : 11.17 (-1.15%)
EBS : 35.82 (-0.33%)
EXEL : 27.41 (-2.49%)
GSK : 41.96 (-0.66%)
What Lies in Store for Glaxo (GSK) this Earnings Season?

The performance of GlaxoSmithKline plc's (GSK) new products is likely to be good. Vaccines acquired from Novartis are likely to drive revenues and ease the impact of the loss of key drug, Advair.

MYL : 38.82 (+0.15%)
NVO : 42.16 (+0.62%)
PFE : 33.10 (-0.66%)
GSK : 41.96 (-0.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

See More

Business Summary

GlaxoSmithKline is one of the world's leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central...

See More

Support & Resistance

2nd Resistance Point 42.38
1st Resistance Point 42.17
Last Price 41.96
1st Support Level 41.78
2nd Support Level 41.60

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.